Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this phase II study was to investigate the efficacy and toxicity of combined ifosfamide and cisplatin chemotherapy in patients with recurrent epithelial ovarian cancer (EOC).

Experimental design

Forty-seven patients with recurrent EOC were treated with ifosfamide 5 g/m2 and cisplatin 50 mg/m2 on day 1, every 3 weeks for 6 cycles. The primary outcomes were response rate (RR) and toxicity. Other measurements were duration of response, time to progression (TTP), and overall survival (OS).

Results

All 47 patients with 160 cycles were assessed for response and toxicity. The overall RR was 31.9 %; there were 3 complete responses (6.4 %) and 12 partial responses (25.5 %). Grade 3 and 4 hematologic toxicities included neutropenia (23.6 %), anemia (12.8 %), and thrombocytopenia (10.7 %). Non-hematologic toxicities were mild, and no drug-related toxic deaths occurred. The median duration of response, TTP, and OS was 5.1, 4.8, and 17.0 months, respectively. In the initially platinum-sensitive group, RR and OS were 44.4 % and 20.4 months, while in the initially platinum-resistant group, these values were 15.0 and 8.7 months, respectively (P = 0.027 and P = 0.002, respectively).

Conclusion

Ifosfamide combined with cisplatin is a well-tolerated regimen with modest activity in recurrent EOC. In addition, this regimen was especially effective in patients whose disease was initially platinum-sensitive.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Marsden DE, Friedlander M, Hacker NF (2000) Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 19:11–19

    Article  PubMed  CAS  Google Scholar 

  2. Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, Mante R, Hord M, Kudelka A (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584–1588

    PubMed  CAS  Google Scholar 

  3. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF (1996) Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2:837–842

    PubMed  CAS  Google Scholar 

  4. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393

    PubMed  CAS  Google Scholar 

  5. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987–993

    PubMed  CAS  Google Scholar 

  6. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63:89–93

    Article  PubMed  CAS  Google Scholar 

  7. Tresukosol D, Kudelka AP, Gonzales de Leon C, Edwards CL, Freedman RS, Mante R, Hord M, Kavanagh JJ (1996) Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaecol Oncol 17:188–191

    PubMed  CAS  Google Scholar 

  8. Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangie T, Scholl S, Sastre X, Pouillart P (1996) Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 6:47–49

    PubMed  CAS  Google Scholar 

  9. Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B, Belinson J (1998) Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 70:272–274

    Article  PubMed  CAS  Google Scholar 

  10. Scarfone G, Villa A, Parazzini F, Sciatta C, Polverino G, Bolis G (1999) A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Tumori 85:217–219

    PubMed  CAS  Google Scholar 

  11. Shaheen M, Stender MJ, McClean JW, Look KY, Einhorn LH (2004) Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. Am J Clin Oncol 27:229–231

    Article  PubMed  CAS  Google Scholar 

  12. Chiara S, Tognoni A, Pastrone I, Tomasello L, Brema F, Di Costanzo G, Folco U, Pronzato P (2004) Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 93:474–478

    Article  PubMed  CAS  Google Scholar 

  13. Salar A, Martino R, Perea G, Ribera JM, Lopez-Guillermo A, Guardia R, Escoda L, Altes A, Sierra J, Montserrat E (2002) High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin’s lymphoma. Haematologica 87:1028–1035

    PubMed  CAS  Google Scholar 

  14. Joly F, Sevin E, Lortholary A, Priou F, Paitel JF, Fabbro M, Henry-Amar M, Hamond K, Bourgeois H (2010) Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. Gynecol Oncol 116:312–316

    Article  PubMed  CAS  Google Scholar 

  15. Joly F, Bourgeois H, Floquet A, Chinet-Charrot P, Meyer F, Lebrun D, Hamond K, Leroy C, Heron JF (2006) Efficacy and tolerability of the ifosfamide–epirubicin combination in relapsed ovarian cancer. Int J Gynecol Cancer 16:77–82

    Article  PubMed  CAS  Google Scholar 

  16. Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A (2000) Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Semin Oncol 27:8–13

    PubMed  CAS  Google Scholar 

  17. Polyzos A, Tsavaris N, Kosmas C, Petrikos G, Giannikos L, Kalahanis N, Papadopoulos O, Christodoulou K, Giannakopoulos K, Veslemes M, Katsilambros N (1999) Second-line chemotherapy with cisplatin–ifosfamide in patients with ovarian cancer previously treated with carboplatin–cyclophosphamide. J Chemother 11:144–149

    PubMed  CAS  Google Scholar 

  18. Cervellino JC, Araujo CE, Sanchez O, Miles H, Nishihama A (1995) Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol 34:257–259

    Article  PubMed  CAS  Google Scholar 

  19. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20:1832–1837

    Article  PubMed  CAS  Google Scholar 

  20. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C (2007) A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 105:399–403

    Article  PubMed  CAS  Google Scholar 

  21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  22. Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EV, Hansen HH (2004) Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22:4051–4058

    Article  PubMed  Google Scholar 

  23. Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21:187s–193s

    Article  PubMed  Google Scholar 

  24. Baur M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H, Dittrich C (2006) Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients—long-term results of a phase II study. Cancer Invest 24:22–27

    Article  PubMed  CAS  Google Scholar 

  25. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J (1989) Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7:1672–1676

    PubMed  CAS  Google Scholar 

  26. Sorensen P, Pfeiffer P, Bertelsen K (1995) A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 56:75–78

    Article  PubMed  CAS  Google Scholar 

  27. Gonzalez-Martin A, Crespo C, Garcia-Lopez JL, Pedraza M, Garrido P, Lastra E, Moyano A (2002) Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. Gynecol Oncol 84:368–373

    Article  PubMed  CAS  Google Scholar 

  28. Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A (2007) Paclitaxel–ifosfamide–cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Anticancer Res 27:1645–1651

    PubMed  CAS  Google Scholar 

  29. Polyzos A, Tsavaris N, Gogas H, Lagadas A, Polyzos K, Giannakopoulos K, Felekouras E, Tsigris C, Karatzas T, Papadopoulos O, Giannopoulos A (2009) Cisplatin–Ifosfamide–gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel. Anticancer Res 29:2681–2686

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea

    Taejong Song

  2. Department of Obstetrics and Gynecology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea

    Min Kyu Kim

  3. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Gangnam-gu, Seoul, 135-710, Korea

    Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim & Duk Soo Bae

Authors
  1. Taejong Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Kyu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoo-Young Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chel Hun Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tae-Joong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeong-Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Byoung-Gie Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Duk Soo Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Duk Soo Bae.

Additional information

Taejong Song and Min Kyu Kim contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Song, T., Kim, M.K., Lee, YY. et al. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer. Cancer Chemother Pharmacol 72, 653–660 (2013). https://doi.org/10.1007/s00280-013-2241-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-013-2241-7

Keywords

Search

Navigation